Clinical Trials
14 trialsNCT04423211 2026-05-15
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04513717 2026-05-04
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05050084 2026-05-04
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT06671548 2026-02-02
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT05862272 2025-08-06
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma Switzerland GmbH
Phase 3 Recruiting
NCT03751124 2024-06-25
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03412890 2024-05-09
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03103087 2022-04-20
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03049735 2022-04-19
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT02655224 2019-03-22
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Takeda
Phase 3 Completed
NCT02655237 2019-03-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Takeda
Phase 3 Completed